Davenport & CO LLC Abb Vie Inc. Transaction History

Davenport & CO LLC

$16.8 Billion
Q3 2024

A detailed history of Davenport & CO LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Davenport & CO LLC holds 171,254 shares of ABBV stock, worth $31 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

171,254

Previous 171,833 0.34%

Holding current value

$31 Million

Previous $29.5 Million 14.75%

% of portfolio

0.2%

Previous 0.18%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$163.84 - $199.33 $94,863 - $115,412	-579 Reduced 0.34%	171,254 $33.8 Million
Q2 2024 Aug 06, 2024	BUY	$154.79 - $180.76 $84,979 - $99,237	549 Added 0.32%	171,833 $29.5 Million
Q1 2024 May 03, 2024	SELL	$159.82 - $182.1 $2.21 Million - $2.51 Million	-13,798 Reduced 7.46%	171,284 $31.2 Million
Q4 2023 Jan 23, 2024	BUY	$137.6 - $154.97 $384,454 - $432,986	2,794 Added 1.53%	185,082 $28.7 Million
Q3 2023 Oct 17, 2023	SELL	$133.59 - $154.65 $1.05 Million - $1.21 Million	-7,851 Reduced 4.13%	182,288 $27.2 Million
Q2 2023 Jul 20, 2023	SELL	$132.51 - $164.9 $371,558 - $462,379	-2,804 Reduced 1.45%	190,139 $25.6 Million
Q1 2023 Apr 27, 2023	SELL	$144.61 - $166.54 $1.26 Million - $1.45 Million	-8,701 Reduced 4.32%	192,943 $30.7 Million
Q4 2022 Jan 20, 2023	BUY	$138.31 - $165.87 $518,939 - $622,344	3,752 Added 1.9%	201,644 $0
Q3 2022 Oct 11, 2022	BUY	$134.21 - $153.93 $62,944 - $72,193	469 Added 0.24%	197,892 $26.6 Million
Q2 2022 Jul 18, 2022	SELL	$137.62 - $174.96 $647,226 - $822,836	-4,703 Reduced 2.33%	197,423 $30.2 Million
Q1 2022 May 02, 2022	BUY	$131.98 - $163.75 $375,351 - $465,705	2,844 Added 1.43%	202,126 $32.8 Million
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $2.32 Million - $2.93 Million	21,588 Added 12.15%	199,282 $27 Million
Q3 2021 Oct 14, 2021	BUY	$106.4 - $120.78 $4.52 Million - $5.13 Million	42,478 Added 31.41%	177,694 $19.2 Million
Q2 2021 Jul 28, 2021	BUY	$105.21 - $117.21 $2.37 Million - $2.64 Million	22,528 Added 19.99%	135,216 $15.2 Million
Q1 2021 Apr 28, 2021	BUY	$102.3 - $112.62 $931,850 - $1.03 Million	9,109 Added 8.79%	112,688 $12.2 Million
Q4 2020 Jan 13, 2021	BUY	$80.49 - $108.67 $132,888 - $179,414	1,651 Added 1.62%	103,579 $11.1 Million
Q3 2020 Oct 15, 2020	SELL	$85.91 - $100.83 $267,695 - $314,186	-3,116 Reduced 2.97%	101,928 $8.93 Million
Q2 2020 Jul 28, 2020	BUY	$73.37 - $98.18 $876,184 - $1.17 Million	11,942 Added 12.83%	105,044 $10.3 Million
Q1 2020 May 05, 2020	BUY	$64.5 - $97.79 $942,603 - $1.43 Million	14,614 Added 18.62%	93,102 $7.09 Million
Q4 2019 Jan 22, 2020	SELL	$72.13 - $90.25 $44,432 - $55,594	-616 Reduced 0.78%	78,488 $6.95 Million
Q3 2019 Oct 16, 2019	BUY	$62.98 - $75.72 $11,840 - $14,235	188 Added 0.24%	79,104 $5.75 Million
Q2 2019 Jul 10, 2019	SELL	$65.7 - $83.98 $129,297 - $165,272	-1,968 Reduced 2.43%	78,916 $5.74 Million
Q1 2019 Apr 17, 2019	SELL	$77.14 - $90.79 $663,404 - $780,794	-8,600 Reduced 9.61%	80,884 $6.52 Million
Q4 2018 Jan 28, 2019	SELL	$77.85 - $96.01 $286,955 - $353,892	-3,686 Reduced 3.96%	89,484 $8.25 Million
Q3 2018 Oct 11, 2018	SELL	$88.91 - $98.84 $751,378 - $835,296	-8,451 Reduced 8.32%	93,170 $8.81 Million
Q2 2018 Jul 09, 2018	BUY	$89.78 - $106.23 $160,436 - $189,833	1,787 Added 1.79%	101,621 $9.42 Million
Q1 2018 Apr 04, 2018	SELL	$92.01 - $123.21 $3.07 Million - $4.12 Million	-33,403 Reduced 25.07%	99,834 $9.45 Billion
Q4 2017 Jan 17, 2018	SELL	$89.56 - $98.21 $214,227 - $234,918	-2,392 Reduced 1.76%	133,237 $12.9 Billion
Q3 2017 Oct 12, 2017	BUY	$69.85 - $89.22 $9.47 Million - $12.1 Million	135,629	135,629 $12.1 Billion

Others Institutions Holding ABBV

# of Institutions

3,849

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $320B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.

Account